Tyrosine kinase inhibitorPhase 3 trialInvestigational
Zanubrutinib
How it works
Blocks the Bruton's tyrosine kinase (BTK) protein, which is involved in the growth and survival of leukemia cells.
Cancer types
Leukemia— All patients
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Zanubrutinib, Obinutuzumab, and Venetoclax for CLL or SLL | Leukemia | phase-2 | — | Source → |
| Study of CLL Treatment Combination | Leukemia | phase-3 | — | Source → |
| Comparing Zanubrutinib and Acalabrutinib in Relapsed CLL | Leukemia | phase-3 | One progression was avoided per 10 patients treated (NNT=10) and one death per 15 patients treated (NNT=15) with zanubrutinib. | Source → |
| New Study Compares Effectiveness of CLL Treatments | Leukemia | meta-analysis | Zanubrutinib had a significantly reduced risk of progression or death compared with ibrutinib (hazard ratio [HR], 0.49; 95% credible interval [CrI], 0.31-0.78). | Source → |
| Zanubrutinib vs Ibrutinib for Chronic Lymphocytic Leukemia: Cost Comparison | Leukemia | phase-3 | Treating 8 patients with zanubrutinib instead of ibrutinib prevented 1 progression or death. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.